ELOVL4 — ELOVL fatty acid elongase 4

The ELOVL4 gene provides instructions for making a protein that acts like a specialized manufacturing machine inside your cells. This machine's job is to build very long-chain fatty acids, which are specific types of fats essential for the health and function of certain tissues in the body. These special fats are particularly important in the retina (the light-sensitive tissue at the back of the eye), the brain, and the skin. In the eye, these fats help maintain the structure of the cells that detect light, allowing you to see clearly. When the ELOVL4 gene is mutated, the protein it makes either doesn't work properly or gets stuck in the wrong part of the cell. If a person inherits one specific type of mutated ELOVL4 gene, it can cause a condition called Stargardt-like macular dystrophy (STGD3). This condition leads to a gradual loss of central vision, usually starting in childhood or young adulthood, because the light-detecting cells in the eye slowly break down without the necessary long-chain fats. Other types of mutations in this gene can cause different problems, such as movement and coordination issues (spinocerebellar ataxia) or severe skin conditions, depending on how the mutation affects the protein's function in the brain or skin. Stargardt-like macular dystrophy and the movement disorders associated with ELOVL4 are typically inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. If a person has the condition, each of their children has a 50% chance of inheriting the mutated gene. Genetic testing can help confirm the diagnosis and provide families with important information about their risks and what to expect.

Gene description: ELOVL4 encodes an enzyme responsible for the synthesis of very long-chain fatty acids, particularly in photoreceptor cells.

Patient and family guide: The ELOVL4 gene provides instructions for making a protein that acts like a specialized manufacturing machine inside your cells. This machine's job is to build very long-chain fatty acids, which are specific types of fats essential for the health and function of certain tissues in the body. These special fats are particularly important in the retina (the light-sensitive tissue at the back of the eye), the brain, and the skin. In the eye, these fats help maintain the structure of the cells that detect light, allowing you to see clearly. When the ELOVL4 gene is mutated, the protein it makes either doesn't work properly or gets stuck in the wrong part of the cell. If a person inherits one specific type of mutated ELOVL4 gene, it can cause a condition called Stargardt-like macular dystrophy (STGD3). This condition leads to a gradual loss of central vision, usually starting in childhood or young adulthood, because the light-detecting cells in the eye slowly break down without the necessary long-chain fats. Other types of mutations in this gene can cause different problems, such as movement and coordination issues (spinocerebellar ataxia) or severe skin conditions, depending on how the mutation affects the protein's function in the brain or skin. Stargardt-like macular dystrophy and the movement disorders associated with ELOVL4 are typically inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. If a person has the condition, each of their children has a 50% chance of inheriting the mutated gene. Genetic testing can help confirm the diagnosis and provide families with important information about their risks and what to expect.

Gene function: ELOVL4 is crucial for the elongation of very long-chain fatty acids (VLCFAs) which are highly abundant in the photoreceptor outer segment membranes. These VLCFAs are essential for the structural integrity and proper function of photoreceptors, playing a vital role in phototransduction and overall retinal health. Defective ELOVL4 function leads to photoreceptor degeneration and vision loss.

Protein structure: The ELOVL4 gene encodes a 314-amino acid multi-pass transmembrane protein with a calculated molecular weight of approximately 36.8 kDa. The protein contains several transmembrane domains that anchor it to the endoplasmic reticulum (ER) membrane. It features a highly conserved histidine-rich motif (HXXHH) that is characteristic of the ELO family of elongases and is essential for its enzymatic activity. A critical structural feature of the ELOVL4 protein is its C-terminal ER-retention signal, which consists of a dilysine motif (KXKXX). This signal ensures that the protein remains localized to the ER, where fatty acid elongation occurs. Truncating mutations that cause STGD3 typically result in the loss of this C-terminal signal, causing the mutant protein to mislocalize to the cytoplasm, form aggresomes, and exert a dominant-negative effect by trapping the wild-type protein.

Molecular function: The ELOVL4 gene encodes Elongation of Very Long Chain Fatty Acids Protein 4, a membrane-bound enzyme localized to the endoplasmic reticulum (ER). It functions as a fatty acid elongase, catalyzing the first and rate-limiting condensation reaction in the elongation cycle of very long-chain fatty acids (VLC-FAs). ELOVL4 is unique in its ability to synthesize both very long-chain saturated fatty acids (VLC-SFAs) and very long-chain polyunsaturated fatty acids (VLC-PUFAs) with carbon chain lengths of 26 to 38 or more. In the retina, ELOVL4 primarily elongates long-chain PUFAs, such as eicosapentaenoic acid (EPA), into VLC-PUFAs. These VLC-PUFAs are esterified into phosphatidylcholine and are highly enriched in the photoreceptor outer segment discs, where they are crucial for maintaining membrane fluidity, facilitating the rapid conformational changes of rhodopsin during phototransduction, and supporting photoreceptor survival. In the skin and brain, ELOVL4 synthesizes VLC-SFAs that are incorporated into ceramides and sphingolipids, which are essential for the epidermal water barrier and myelin stability, respectively.

Expression pattern: The ELOVL4 gene is primarily expressed in the retina, specifically enriched in the inner segments of rod and cone photoreceptors. It is also expressed in the brain, particularly in the cerebellum, and in the skin, testes, and meibomian glands. During development, ELOVL4 expression increases as these tissues mature and require very long-chain fatty acids for structural and functional specialization. In the retina, its expression is critical for the synthesis of VLC-PUFAs that are incorporated into the photoreceptor outer segment membranes. In the skin, it is expressed in the epidermis where it is essential for the production of very long-chain ceramides necessary for the epidermal water barrier.

Mutation spectrum: The mutation spectrum of ELOVL4 includes frameshift deletions, nonsense mutations, and missense mutations, which lead to distinct clinical phenotypes. The most well-known mutations are heterozygous frameshift deletions (e.g., a 5-bp deletion) and nonsense mutations in exon 6, which cause STGD3. These mutations cluster in the C-terminal region, leading to the loss of the ER-retention signal. Missense mutations are distributed throughout the gene and are typically associated with SCA34 or the recessive neuro-ichthyotic syndrome. A significant founder effect has been observed for the 5-bp deletion (c.797_801delAACTT) in North American families with STGD3, tracing back to a common ancestor. To date, several dozen pathogenic variants have been reported in databases like ClinVar, reflecting the gene's pleiotropic roles in different tissues.

Pathogenic variants: 1. c.797_801delAACTT (p.Asn266LysfsTer5) - A 5-bp deletion in exon 6 that is the most common cause of Autosomal Dominant Stargardt-like Macular Dystrophy (STGD3), exhibiting a strong founder effect in North America. 2. c.810C>G (p.Tyr270Ter) - A nonsense mutation in exon 6 that truncates the protein, leading to STGD3 by a similar dominant-negative mechanism as the 5-bp deletion. 3. c.736T>G (p.Trp246Gly) - A missense mutation associated with Spinocerebellar Ataxia-34 (SCA34) and Erythrokeratodermia variabilis, affecting cerebellar and skin function. 4. c.502C>T (p.Leu168Phe) - Another missense mutation that causes SCA34, demonstrating the distinct phenotypic outcome of missense versus truncating mutations in ELOVL4. 5. c.698C>T (p.Thr233Met) - A missense variant reported as pathogenic/likely pathogenic, contributing to the spectrum of ELOVL4-related neurological or dermatological disorders.

Clinical significance: Mutations in the ELOVL4 gene manifest clinically in several distinct ways depending on the specific mutation and inheritance pattern. Heterozygous mutations, typically truncating mutations in exon 6, cause Autosomal Dominant Stargardt-like Macular Dystrophy (STGD3). STGD3 is characterized by juvenile-onset progressive central vision loss, macular atrophy, and the presence of yellow flecks in the fundus, with symptom onset usually in the first or second decade of life. The severity and progression can vary even within families, leading to legal blindness by young adulthood. Heterozygous missense mutations in different regions of the gene cause Spinocerebellar Ataxia-34 (SCA34), sometimes associated with Erythrokeratodermia variabilis (EKV). This condition presents with adult-onset progressive cerebellar ataxia, dysarthria, and in some cases, skin abnormalities characterized by transient erythematous patches and hyperkeratosis. Homozygous or compound heterozygous mutations in ELOVL4 result in a severe, often lethal, neuro-ichthyotic disorder characterized by ichthyosis, spastic quadriplegia, and intellectual disability (ISQMR), highlighting the critical role of ELOVL4 in skin barrier function and brain development.

Inheritance: Autosomal Dominant

Chromosomal location: 6q14.1

Genotype-phenotype correlations: There is a strong genotype-phenotype correlation for ELOVL4 mutations. Heterozygous frameshift or nonsense mutations in exon 6 (e.g., the 5-bp deletion c.797_801delAACTT) lead to a truncated protein that loses its ER-retention signal. This results in Autosomal Dominant Stargardt-like Macular Dystrophy (STGD3) due to a dominant-negative effect where the mutant protein sequesters the wild-type protein in the retina. Conversely, heterozygous missense mutations (e.g., p.Leu168Phe, p.Trp246Gly) typically cause Spinocerebellar Ataxia-34 (SCA34), with or without Erythrokeratodermia variabilis. These mutations affect the enzymatic activity of ELOVL4 in the brain and skin without necessarily causing retinal degeneration. Biallelic (homozygous or compound heterozygous) mutations, which severely impair or abolish ELOVL4 function, result in the profound neuro-ichthyotic syndrome (ichthyosis, spastic quadriplegia, and intellectual disability), reflecting the absolute requirement of ELOVL4 for normal skin barrier and neurological development.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies specifically for ELOVL4-related diseases, and management is primarily supportive, focusing on low-vision aids for STGD3 and symptomatic treatment for neurological and dermatological manifestations. However, several therapeutic strategies are under investigation. Gene therapy is a major focus, with preclinical studies demonstrating that viral-mediated transfer of the wild-type ELOVL4 gene can be efficiently accomplished in retinal pigment epithelium (RPE) cells and photoreceptors. Adeno-associated virus (AAV) vectors are being explored to deliver functional ELOVL4 to the retina to compensate for the loss of VLC-PUFAs, although overcoming the dominant-negative effect of the mutant protein remains a challenge. Other pipeline approaches include pharmacological interventions aimed at alleviating endoplasmic reticulum (ER) stress caused by the mislocalized mutant protein. Dietary supplementation with specific fatty acids, such as eicosapentaenoic acid (EPA), has been investigated in animal models to bypass the enzymatic block or reduce ER stress, though clinical trials (e.g., NCT00420602) evaluating fish oil supplements in STGD3 patients have not shown significant attenuation of disease progression. Additionally, observational natural history studies (e.g., NCT04591483) are ongoing to better understand disease progression and identify clinical endpoints for future therapeutic trials.

Diagnostic testing: Mutations in the ELOVL4 gene are typically detected through targeted gene panel testing for inherited retinal diseases, spinocerebellar ataxias, or ichthyosis, depending on the clinical presentation. Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be employed, particularly in cases with complex or overlapping phenotypes. Genetic counseling is essential for affected individuals and their families. For STGD3 and SCA34, which are inherited in an autosomal dominant manner, each child of an affected individual has a 50% chance of inheriting the mutation. For the severe neuro-ichthyotic phenotype, which is autosomal recessive, parents are obligate carriers, and there is a 25% recurrence risk for subsequent pregnancies. Counseling should address the variable expressivity and age of onset, particularly for the dominant conditions.

Animal models: Key animal models for ELOVL4 include transgenic and knock-in mice, which have been instrumental in understanding disease mechanisms. The Elovl4 5-bp deletion knock-in mouse model and transgenic mice expressing the mutant ELOVL4 protein develop progressive photoreceptor degeneration, retinal pigment epithelial (RPE) changes, and accumulation of lipofuscin, closely mimicking human Stargardt-like macular dystrophy (STGD3). These models revealed that the mutant ELOVL4 protein exerts a dominant-negative effect, mislocalizing to the cytoplasm and forming aggresomes that sequester the wild-type protein, leading to a deficiency in very long-chain polyunsaturated fatty acids (VLC-PUFAs) and inducing endoplasmic reticulum (ER) stress. Zebrafish models have also been utilized to study the developmental role of ELOVL4 in the retina and brain, confirming its conserved function in VLC-FA biosynthesis across species.

Population genetics: ELOVL4 mutations are rare in the general population. However, a significant founder effect has been identified for the 5-bp deletion (c.797_801delAACTT) causing STGD3. Haplotype analysis of multiple North American families with this mutation revealed that they share a common ancestor, explaining the higher prevalence of this specific variant in that region. The carrier frequency for recessive ELOVL4 mutations causing the severe neuro-ichthyotic phenotype is extremely low, and these cases often occur in consanguineous families or isolated populations.

Selected references: 1. Zhang K, et al. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet, 2001. PMID: 11138005 2. Edwards AO, et al. A novel gene for autosomal dominant Stargardt-like macular dystrophy with homology to a yeast gene involved in very long chain fatty acid elongation. Am J Hum Genet, 2001. PMID: 11133352 3. Agbaga MP, et al. Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proc Natl Acad Sci U S A, 2008. PMID: 18728184 4. Karan G, et al. Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor degeneration in mutant ELOVL4 transgenic mice: a model for macular degeneration. Proc Natl Acad Sci U S A, 2005. PMID: 15749821 5. Maugeri A, et al. A novel mutation in the ELOVL4 gene causes autosomal dominant Stargardt-like macular dystrophy. Invest Ophthalmol Vis Sci, 2004. PMID: 15557430 6. Bourassa CV, et al. A novel mutation in ELOVL4 leading to spinocerebellar ataxia (SCA34) with erythrokeratodermia. JAMA Neurol, 2015. PMID: 26010696 7. Aldahmesh MA, et al. Recessive mutations in ELOVL4 cause ichthyosis, intellectual disability, and spastic quadriplegia. Am J Hum Genet, 2011. PMID: 22152678